ストックスクリーナーアプリを入手
2.66
5.14%
0.13
アフターアワーズ：
2.66
前日終値:
$2.53
開ける：
$2.5
24時間の取引高:
437.38K
Relative Volume:
1.04
時価総額：
$247.69M
収益：
$64.70M
当期純損益:
$-123.43M
株価収益率:
-11.08
EPS:
-0.24
ネットキャッシュフロー:
$-95.23M
1週間 パフォーマンス:
+8.57%
1か月 パフォーマンス:
+1.92%
6か月 パフォーマンス:
-7.32%
1年 パフォーマンス:
+8.57%
1日の値動き範囲:
$2.48
$2.66
1週間の範囲:
$2.32
$2.66
52週間の値動き範囲:
$1.87
$4.27
Poseida Therapeutics Inc Stock (PSTX) Company Profile
名前
Poseida Therapeutics Inc
セクター
電話
858-779-3100
住所
9390 TOWNE CENTRE DRIVE, SAN DIEGO
Poseida Therapeutics Inc Stock (PSTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-04 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-18 | 開始されました | BTIG Research | Buy |
| 2020-08-04 | 開始されました | BofA Securities | Buy |
| 2020-08-04 | 開始されました | Piper Sandler | Overweight |
| 2020-08-04 | 開始されました | William Blair | Outperform |
すべてを表示
Poseida Therapeutics Inc (PSTX) 最新ニュース
Poseida Therapeutics to present cancer cell therapy data at SITC, ASH - Investing.com
Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 - PR Newswire
Poseida Therapeutics (STU:2RZ) Degree of Operating Leverage : -9.17 (As of Jun. 2024) - GuruFocus.com
Poseida Therapeutics' (PSTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Poseida Therapeutics Receives Regenerative Medicine Advanced The - GuruFocus.com
Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PR Newswire
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30% - Simply Wall St
Third development candidate nominated under Poseida and Roche’s allogeneic CAR T collaboration - BioWorld Online
Poseida shares hold as analyst reiterates buy rating on MM study - Investing.com
Poseida Nominates New Development Candidate Under Its Collaboration With Roche - Contract Pharma
Poseida Therapeutics (NASDAQ:PSTX) Rating Reiterated by HC Wainwright - MarketBeat
Poseida advances with new CAR-T therapy candidate - Investing.com
Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - StockTitan
Quarterly Metrics: Quick and Current Ratios for Poseida Therapeutics Inc (PSTX) - The Dwinnex
Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
The Anatomy Of Astellas And Poseida's CAR-T Deal - In Vivo
PSTXPoseida Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™
Ratio Examination: Poseida Therapeutics Inc (PSTX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Poseida Therapeutics Inc (PSTX) deserves closer scrutiny - US Post News
Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - IT News Online
Poseida Therapeutics (STU:2RZ) Long-Term Capital Lease Obli - GuruFocus.com
Poseida Therapeutics (STU:2RZ) Net Change in Cash : €-18.49 Mil (TTM As of Jun. 2024) - GuruFocus.com
Anchoring Your Portfolio: Is PSTX Stock a Safe Harbor? - The InvestChronicle
Poseida Therapeutics, Inc. (NASDAQ:PSTX) Shares Acquired by Renaissance Technologies LLC - MarketBeat
Roche-Poseida Lead Allogeneic CAR-T Advances after Showing Promise in Multiple Myeloma - Genetic Engineering & Biotechnology News
A new trading data show Poseida Therapeutics Inc (PSTX) is showing positive returns. - SETE News
Poseida stock supported by strong data from P-BCMA-ALLO-1, says BTIG - Investing.com South Africa
Piper Sandler maintains Overweight rating on Poseida Therapeutics shares - Investing.com
Poseida Therapeutics' SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com India
Poseida Therapeutics reveals promising trial results for myeloma treatment - Investing.com
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement - Seeking Alpha
What technical indicators reveal about PSTX stock - US Post News
Metric Analysis: Poseida Therapeutics Inc (PSTX)’s Key Ratios in the Limelight - The Dwinnex
Poseida Therapeutics' SWOT analysis: gene therapy stock shows promise amid challenges By Investing.com - Investing.com South Africa
Piper Sandler maintains Overweight rating on Poseida Therapeutics shares By Investing.com - Investing.com UK
Poseida reports high response in multiple myeloma trial - Investing.com India
Poseida reports high response in multiple myeloma trial By Investing.com - Investing.com South Africa
Poseida Therapeutics Study of Prospective Myeloma Treatment Yields Positive Data - Marketscreener.com
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients - PR Newswire
How did Poseida Therapeutics Inc (PSTX) fare last session? - US Post News
Pivotree (CVE:PVT) Shares Up 3% - Defense World
Provident Financial Services And 4 Other Stocks Have High Sales Growth And An Above 3% Return on Equity - Via News Agency
Poseida Therapeutics Garners FDA RMAT Designation for Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma - CGTLive™
Altrius Capital Management Inc Buys 15,174 Shares of POSCO Holdings Inc. (NYSE:PKX) - Defense World
Poseida Therapeutics Inc (PSTX) Stock: A Year of Market Fluctuations - The InvestChronicle
Piper Sandler maintains Overweight rating on Opko Health shares on strong prospects - Investing.com Canada
FDA grants Poseida’s CAR T-cell therapy RMAT status for RRMM - Myeloma Research News
FDA grants RMAT status to Poseida’s P-BCMA-ALLO1 for relapsed/refractory multiple myeloma - World Pharmaceutical Frontiers
FDA grants RMAT status to Poseida's multiple myeloma therapy By Investing.com - Investing.com Canada
FDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1 - Pharmaceutical Technology
Poseida Therapeutics Inc (PSTX) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):